Introduction:
Infections with methicillin resistant Staphylococcus aureus (MRSA) pathogens represent a substantial economic burden for the healthcare system. As the main cost driver, the increase in the length of stay (LOS) in hospital has been identified. The expenses directly related to the antibiotics used for the treatment of MRSA infections, in contrast, were found to be relatively marginal. Nevertheless, the purchase price of an antibiotic is often used as a criterion for the decision regarding the appropriate antibiotic treatment (e.g. [1]).
Objectives:
The objective of this study was to investigate -in a clinical routine setting -the overall costs of stay in intensive care unit (ICU) and the clinical effectiveness of treatment with linezolid (LIN) compared to vancomycin (VAN) in patients with MRSA pneumonia.
Methods:
This was a retrospective, explorative analysis of reimbursement and medical data of patients who met the following inclusion criteria:
• Patient (≥ 18 years of age with any primary or secondary disease and microbiologically confirmed MRSA pneumonia.
• The patient was treated for MRSA pneumonia with either LIN or VAN as the sole MRSA-effective initial therapy.
• The treatment took place at a study center (German hospital) between 01/2008 and 12/2012.
The primary data source was reimbursement (diagnosis-related groups [DRG] ) and costing data. Information on antibiotic treatment, microbiology and therapy success was retrieved from the patients' medical records. To reduce the effect of confounding, propensity score adjustment was applied in all statistical models used. Prior to the start of the study, the approval of the relevant independent ethics committee was obtained.
Results:
Data base:
• 10 university and maximum care hospitals in Germany submitted the data of all their patients who met the above inclusion criteria.
• 226 patients were included in total.
• 95 of these patients received LIN, 131 received VAN.
• The majority of patients were male and ≥ 50 years of age (Table 2 ).
• Diseases of the circulatory and respiratory system were the most common principal and secondary diagnoses. A principal diagnosis of MRSA pneumonia was relatively uncommon (13.3%).
• Any between-group differences in the presumed key pre-treatment characteristics were taken into account by applying propensity score methods.
Stay in ICU and therapy for MRSA pneumonia:
• Most patients (96.3%) were in the ICU for at least one day after the start of MRSA therapy.
• The LOS in ICU varied considerably within the two treatment groups ( Figure  1 ). Between group differences were small.
• In both groups, the mean LOS in ICU after the start of MRSA therapy by far exceeded the mean duration of the MRSA therapy ( Figure 1 ).
• The likelihood of being switched to another antibiotic after treatment day 5 (interpreted as therapy failure) was lower in the LIN group than in the VAN group ( Figure 2 ).
• The risk of dying in hospital (all-cause in-hospital mortality rate) was also lower in the LIN group (Figure 2 ).
• The estimated median time to death was 120 days in the LIN group and 60 days in the VAN group (Figure 2 ).
Total costs of stay in ICU:
• The LOS in ICU and the costs of stay in ICU were closely correlated (Figure 1 ).
• The distribution of the costs of stay in ICU was noticeably skewed to the right. In both groups, the mean costs of stay in ICU were higher than the median costs due to the influence of single outliers, i.e., cases with extremely long stays in ICU (Figure 1 ; Figure 3 ).
• A detailed analysis of individual patient data showed that the most extreme LOS in ICU were unrelated to the MRSA infection.
• The generalized-linear-model based analysis of the complete data set indicated no significant difference between the two treatment groups regarding the costs of stay in ICU (Figure 1 ; Table 1 ).
• This finding is in line with the results of sensitivity analyses based on outlieradjusted data ( • Another factor possibly co-responsible for the differences in the mean costs of stay in ICU were between-group differences in the all-cause mortality rate, since, on average, the costs of stay in ICU were lower in patients who died in hospital than in patients who survived (Figure 3 ).
ICU costs, drug costs & survival odds:
• Differences in ICU costs and drug acquisition costs (i.e., additional costs of approx. €100/day when LIN was used instead of VAN) have to be set against the total costs of stay in ICU and the different survival odds.
• The extra costs per life saved were estimated by applying the different survival rates to the mean costs of stay in ICU in the two groups (incremental costeffectiveness ratio). For the study population as a whole, these were estimated as €314 per life saved when linezolid instead of vancomycin was used for the treatment of MRSA pneumonia. 10 patients with costs of € 0 and above approx. €100, 000 (top 5%) were replaced by the 5 th or 95 th percentile, respectively (6 patients in the linezolid group and 4 patients in the vancomycin group). Box-plot: Using the box-plot method with untransformed data, 13 patients with costs above approx. €95, 000 were identified as outliers and excluded from analysis. Box-plot (ln data): Using the box-plot method with ln-transformed data, 15 patients with costs of € 0 were identified as outliers and excluded from analysis. DFBETAs: Based on DFBETAs, 4 patients in the linezolid group with costs above € 150, 000 were identified as influential observations and excluded from analysis. (One patient in the vancomycin group with costs >€150,000 Euro was not identified as "influential" and thus not excluded.) Cook's distance: Based on Cook's distance, 7 patients with costs above € 90, 000 were identified as influential and excluded from analysis.
Conclusion:
Despite higher drug acquisition costs, the total costs of stay in ICU were not significantly higher in patients receiving linezolid than in patients receiving vancomycin.
On the other hand, there were indications that the clinical effectiveness of linezolid might be superior to that of vancomycin: Both, the rate of therapy failures and the all-cause hospital mortality rate were substantially lower in patients who received linezolid.
However, further (prospective) research in real-life patient populations is necessary. The PCCL is a measure of the cumulative effect of complications and comorbidities. A high PCCL indicates the presence of complications or co-morbidities that are expected to affect the length and the costs of stay in hospital. (The PCCL was calculated according to the German DRG system.) Note: Any between-group differences in the presumed key pre-treatment characteristics were taken into account by applying propensity score methods.
